US Defense finishes latest research on Immuron’s Travelan®
The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.
https://finfeed.com/small-caps/biotech/us-defense-finishes-latest-research-on-immurons-travelan/
Filter by Year:
- Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
- Immuron and US Department of Defense look to develop silver bullet for gastro infections
- Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
- Blockbuster Results from IMC’s NASH Liver Therapy Trials
- Immuron reports positive clinical study results in the fight against fatty liver disease
- Results in: IMC’s lead drug reduces major factor in liver inflammation
- US Defense finishes latest research on Immuron’s Travelan®
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
